SION
Sionna Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Sionna Therapeutics, Inc.
Expected move
No implied move.
Next report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Sionna Therapeutics, Inc.
3.88
Linked news
Sionna Therapeutics has 4 disclosed suppliers and 0 disclosed customers in SEC filings.
—
SentenceIn December 2019, we entered into a license agreement, which has been subsequently amended (as amended, the "Sanofi License Agreement"), with Sanofi, pursuant to which we have been granted an exclusive, worldwide, sublicensable, royalty-bearing license to develop and commercialize products using the licensed compounds and know-how for CFTR modulator therapies.
SentenceAs initial consideration for CFF's grant of, and forbearance from exercising, its rights under the CFFT-Genzyme Agreement, we issued CFF 300,300 shares of our Series Seed preferred stock.
SION 10-Kaccession 0001628280-26-012996
SentenceIn particular, certain of the licensed patents and other intellectual property rights were developed by or on behalf of Galapagos and are sublicensed to us subject to the terms of the second amended and restated collaboration agreement between Galapagos and AbbVie in October 2018 (the "Galapagos License Agreement"), as amended by a side letter between Galapagos and AbbVie in July 2024.
SION 10-Kaccession 0001628280-26-012996